VERU... ratings
Veru Inc. (NASDAQ:VERU) traded up 5% during mid-day trading on Thursday . The stock traded as high as $10.02 and last traded at $9.66. 3,440,872 shares were traded during mid-day trading, a decline of 13% from the average session volume of 3,938,752 shares. The stock had previously closed at $9.20.
Several analysts have issued reports on the stock. HC Wainwright raised their price target on shares of Veru from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Thursday, December 10th. Brookline Capital Management raised their price target on shares of Veru from $13.00 to $17.00 in a research report on Monday, December 14th. Zacks Investment Research lowered shares of Veru from a “buy” rating to a “hold” rating in a research report on Thursday, December 17th. Cantor Fitzgerald lifted their target price on shares of Veru from $6.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, December 14th. Finally, Oppenheimer lifted their target price on shares of Veru from $9.00 to $19.00 and gave the company an “outperform” rating in a research report on Wednesday, December 16th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Veru presently has an average rating of “Buy” and a consensus target price of $13.15.
The company has a market cap of $623.32 million, a price-to-earnings ratio of -55.59 and a beta of 0.21. The company’s fifty day moving average price is $7.35 and its two-hundred day moving average price is $3.94.
Veru (NASDAQ:VERU) last released its quarterly earnings results on Tuesday, December 8th. The company reported $0.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.07. The company had revenue of $11.75 million during the quarter, compared to analysts’ expectations of $10.64 million. Veru had a negative net margin of 25.78% and a negative return on equity of 30.37%. Equities analysts predict that Veru Inc. will post -0.16 EPS for the current year.
In other news, CEO Mitchell Shuster Steiner sold 250,000 shares of the business’s stock in a transaction on Wednesday, December 16th. The shares were sold at an average price of $9.69, for a total value of $2,422,500.00. Following the sale, the chief executive officer now owns 7,184,767 shares of the company’s stock, valued at $69,620,392.23. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider K Gary Barnette sold 100,000 shares of the business’s stock in a transaction on Wednesday, December 16th. The stock was sold at an average price of $10.65, for a total transaction of $1,065,000.00. The disclosure for this sale can be found here. 26.10% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of VERU. BlackRock Inc. grew its stake in shares of Veru by 4.5% in the third quarter. BlackRock Inc. now owns 3,189,096 shares of the company’s stock valued at $8,355,000 after acquiring an additional 138,551 shares in the last quarter. Kestra Private Wealth Services LLC acquired a new position in shares of Veru in the third quarter valued at about $1,592,000. State Street Corp grew its stake in shares of Veru by 4.1% in the third quarter. State Street Corp now owns 553,976 shares of the company’s stock valued at $1,451,000 after acquiring an additional 21,802 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Veru by 5.6% in the third quarter. Arrowstreet Capital Limited Partnership now owns 389,663 shares of the company’s stock valued at $1,021,000 after acquiring an additional 20,591 shares in the last quarter. Finally, Squarepoint Ops LLC grew its stake in Veru by 142.1% during the third quarter. Squarepoint Ops LLC now owns 312,311 shares of the company’s stock worth $818,000 after buying an additional 183,288 shares in the last quarter. 23.13% of the stock is currently owned by hedge funds and other institutional investors.
Veru Company Profile ( NASDAQ:VERU)
Veru Inc, an oncology biopharmaceutical company, engages in developing medicines for prostate cancer treatment and prostate cancer supportive care. The company's drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in Phase II clinical trial for the treatment of metastatic castration resistant prostate cancer, planned Phase IIb clinical trial for the treatment of taxane resistant metastatic triple negative breast cancer, and Phase II clinical trial for the treatment of COVID-19. |
